Mustang Bio, Inc. (MBIO)
NASDAQ: MBIO · Real-Time Price · USD
1.220
+0.010 (0.83%)
At close: Nov 14, 2025, 4:00 PM EST
1.170
-0.050 (-4.10%)
After-hours: Nov 14, 2025, 6:42 PM EST
Mustang Bio Employees
Mustang Bio had 6 employees as of December 31, 2024. The number of employees decreased by 74 or -92.50% compared to the previous year.
Employees
6
Change (1Y)
-74
Growth (1Y)
-92.50%
Revenue / Employee
n/a
Profits / Employee
-$389,167
Market Cap
8.83M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | -74 | -92.50% |
| Dec 31, 2023 | 80 | -33 | -29.20% |
| Dec 31, 2022 | 113 | 11 | 10.78% |
| Dec 31, 2021 | 102 | 40 | 64.52% |
| Dec 31, 2020 | 62 | 11 | 21.57% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MBIO News
- 4 months ago - Dow Dips 1%; Mustang Bio Shares Spike Higher - Benzinga
- 4 months ago - Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma - GlobeNewsWire
- 9 months ago - Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement - GlobeNewsWire
- 9 months ago - Mustang Bio Announces Sale of Fixed Assets and Exit of Facility - GlobeNewsWire
- 9 months ago - Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 9 months ago - Mustang Bio Announces Closing of $8 Million Public Offering - GlobeNewsWire
- 10 months ago - Mustang Bio Announces Pricing of $8 Million Public Offering - GlobeNewsWire
- 10 months ago - Mustang Bio Announces Reverse Stock Split - GlobeNewsWire